25 citations
,
July 1994 in “Archives of Dermatology” A man's skin condition, pemphigus vulgaris, came back after he was treated with interleukin 2 for cancer.
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Blocking JAK1 or JAK3 helps reverse hair loss in a mouse model of alopecia areata.
March 2026 in “Lithuanian University of Health Sciences” JAK inhibitors can effectively regrow hair in alopecia areata patients, but ongoing treatment is needed to maintain results.
June 2025 in “British Journal of Dermatology” Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
18 citations
,
February 2023 in “eLife” ILC1-like cells can independently cause alopecia areata.
April 2023 in “Journal of Investigative Dermatology” RNase L suppresses regeneration in mammals.
April 2026 in “Case Reports in Dermatology” Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
52 citations
,
September 2014 in “Nature medicine” JAK inhibitors might help treat alopecia areata.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
7 citations
,
December 2021 in “European Respiratory Review” The document concludes that diagnosing and treating Interstitial Pneumonia with Autoimmune Features (IPAF) is challenging, needs a multidisciplinary approach, and further research for better diagnostic criteria and treatments. It also emphasizes regular checks for Connective Tissue Disease symptoms in all patients with Interstitial Lung Disease.
December 2024 in “Kufa Medical journal” Higher levels of IL-17A and IL-2 are linked to alopecia areata.
31 citations
,
July 1975 in “PubMed” Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.
1 citations
,
July 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Tofacitinib helps improve skin conditions in people with Down syndrome, especially alopecia areata.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Removing certain immune cells in mice causes their hair to enter the growth phase earlier than usual.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
November 2024 in “Dermatology Online Journal” Dupilumab may help treat alopecia areata, but more research is needed.
June 2025 in “International Journal of Environmental Sciences” CLEC10A and interleukin-42 can help identify PCOS patients' response to Metformin treatment.
January 2024 in “Inflammation and regeneration” Th22 cells are essential for Tβ15-induced hair growth in mice.
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
28 citations
,
June 2021 in “Frontiers in immunology” A protein called lfTSLP is important in causing allergic and other skin diseases and could be a target for treatment.
3 citations
,
July 2022 in “European Journal of Dermatology” Brodalumab is more effective than ustekinumab for treating psoriasis.
15 citations
,
October 2014 in “The journal of investigative dermatology/Journal of investigative dermatology” Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.
5 citations
,
October 2024 in “Reumatismo” Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
April 2023 in “Journal of Investigative Dermatology” IL-17 plays a key role in severe hair loss in chronic alopecia areata.
Mycophenolate mofetil is a good alternative for autoimmune hepatitis patients who can't tolerate azathioprine.
7 citations
,
February 2023 in “Inflammation and Regeneration” The protein interleukin-1 alpha helps regenerate hair follicles and increase stem cell growth in mice.
April 2021 in “Journal of Investigative Dermatology” TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
51 citations
,
March 2022 in “Frontiers in Immunology” Alarmin cytokines are key in controlling skin immunity and inflammation.
April 2017 in “Journal of Investigative Dermatology” HPH-15, a new compound, effectively reduces skin fibrosis in experiments without causing harm.